<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02944734</url>
  </required_header>
  <id_info>
    <org_study_id>SP-AC-002</org_study_id>
    <nct_id>NCT02944734</nct_id>
  </id_info>
  <brief_title>Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy vs. Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shin Poong Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shin Poong Pharmaceutical Co. Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the optimal dose of fixed-dose combination of
      candesartan cilexetil and amlodipine besylate by examining the safety and efficacy of the
      combination therapy compared to each of the monotherapy in patients with essential
      hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change mean sitting Diastolic Blood Pressure (msDBP) at week 8 compared to baseline</measure>
    <time_frame>Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change mean sitting Diastolic Blood Pressure (msDBP) at week 4 compared to baseline</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change mean sitting Systolic Blood Pressure (msSBP) at week 4 and 8 compared to baseline</measure>
    <time_frame>Week 4 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving treatment goal at week 4 and 8: &lt; 140/90 mmHg</measure>
    <time_frame>Week 4 and 8</time_frame>
    <description>Joint National Committee VII Guideline Treatment goal: &lt; 140/90 mmHg (&lt; 130/80 mmHg, diabetic or chronic renal failure patient)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure Response rate at week 4 and 8: msSBP reduction ≥ 20 mmHg and msDBP reduction ≥ 10 mmHg</measure>
    <time_frame>Week 4 and 8</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">392</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>Candesartan Cilexetil (CC) 8mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candesartan Cilexetil 8mg, once a day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC 16mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candesartan Cilexetil 16mg, once a day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine(AML) 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amlodipine 5mg, once a day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AML 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amlodipine 10mg, once a day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC 8mg / AML 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candesartan 8mg and Amlodipine 5mg, once a day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC 8mg / AML 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candesartan 8mg and Amlodipine 10mg, once a day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC 16mg / AML 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candesartan 16mg and Amlodipine 5mg, once a day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC 16mg / AML 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candesartan 16mg and Amlodipine 10mg, once a day for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan Cilexetil 8mg</intervention_name>
    <description>Candesartan Cilexetil 8mg Daily oral administration for 8 weeks</description>
    <arm_group_label>Candesartan Cilexetil (CC) 8mg</arm_group_label>
    <arm_group_label>CC 8mg / AML 5mg</arm_group_label>
    <arm_group_label>CC 8mg / AML 10mg</arm_group_label>
    <other_name>Atacand 8mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan Cilexetil 16mg</intervention_name>
    <description>Candesartan Cilexetil 16mg Daily oral administration for 8 weeks</description>
    <arm_group_label>CC 16mg</arm_group_label>
    <arm_group_label>CC 16mg / AML 5mg</arm_group_label>
    <arm_group_label>CC 16mg / AML 10mg</arm_group_label>
    <other_name>Atacand 16mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 5mg</intervention_name>
    <description>Amlodipine 5mg Daily oral administration for 8 weeks</description>
    <arm_group_label>Amlodipine(AML) 5mg</arm_group_label>
    <arm_group_label>CC 8mg / AML 5mg</arm_group_label>
    <arm_group_label>CC 16mg / AML 5mg</arm_group_label>
    <other_name>Norvasc 5mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 10mg</intervention_name>
    <description>Amlodipine 10mg Daily oral administration for 8 weeks</description>
    <arm_group_label>AML 10mg</arm_group_label>
    <arm_group_label>CC 8mg / AML 10mg</arm_group_label>
    <arm_group_label>CC 16mg / AML 10mg</arm_group_label>
    <other_name>Norvasc 10mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients greater than or equal to 19 years of age

          2. Subject who was diagnosed with essential hypertension or after administer the
             antihypertensive drug (Subject who may temporarily suspend antihypertensive treatment
             based on doctor's decision)

          3. Subject who have voluntarily agreed to participate in the trial and signed the written
             informed consent form

        Exclusion Criteria:

          1. Subject with severe hypertension (in a selected arm with msSBP ≥ 200 mmHg or msDBP ≥
             115 mmHg) during the Screening and Randomized Trial.

          2. Subject with difference of the blood pressure of over 20 mmHg for SBP or 10 mmHg for
             diastolic blood pressure (DSP) between three consecutive measurements in a selected
             arm during the screening visit

          3. Secondary hypertension (such as, coarctation of the aorta, primary hyperaldosteronism,
             renal artery stenosis, Cushing's disease, pheochromocytoma, polycystic kidney disease,
             etc.)

          4. Symptomatic orthostatic hypotension

          5. Severe heart failure( New York Heart Association(NYHA) Class III/IV)

          6. Subject with acute coronary syndrome(myocardial infarction or unstable angina),
             peripheral vascular disease within the past 6 months

          7. History of switching to another Antiarrhythmic drugs(not including electrolyte
             correction), or received Cardioversion or ICU treatment within the past 6 months

          8. Type 1 diabetes mellitus or Uncontrolled Type 2 diabetes mellitus (HbA1c &gt; 9.0%)

          9. Subject with Haemodynamic disturbance, heart valve disease with structural defects

         10. Severe cerebrovascular disease (stroke, cerebral infarction, or cerebral hemorrhage,
             etc. within the past 6 months)

         11. Severe eye disease (retinal hemorrhage, visual impairment, retinal microaneurysm, etc.
             within the past 6 months)

         12. Autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, etc.)

         13. Chronic inflammatory disease requiring continuous anti-inflammatory treatment

         14. Clinically significant Renal or liver impairment, or laboratory abnormalities such as
             Ccr: below 30ml/min or Aspartate Aminotransferase (AST) or Alanine Aminotransferase
             (ALT) &gt; 3 x Upper Limit Normal (ULN)

         15. Hypokalaemia(Serum potassium &lt; 3.5 mmol/L) or hyperkalaemia(Serum potassium &gt; 5.5
             mmol/L)

         16. Subject with gastrointestinal disease(such as Crohn's disease, gastric ulcer, acute or
             chronic pancreatitis) or history of gastrointestinal surgery(not including
             appendectomy or hernia surgery) that might significantly alter the absorption of the
             drug

         17. history of allergy or hypersensitivity to Angiotensin II Receptor
             Blockers(Candesartan) or Calcium Channel Blocker(amlodipine)

         18. Subject with heredity defects such as galactose intolerance, Lapp lactose deficiency,
             or glucose-galactose malabsorption

         19. Subject requiring concomitant use of other antihypertensive or contraindicated drugs(
             Tizanidine, dolasetron, Itraconazole, potassium, potassium-sparing diuretics, etc.)
             during the clinical trial

         20. history of malignant tumors within the past 5 years

         21. history of alcohol or drug abuse

         22. Pregnant women and lactating mothers

         23. Women who is planning to be pregnant during or 2 months after the study, or women or
             men who are not using medically acceptable methods of contraception *

             * progestin oral or implant contraceptive, intra-uterine device, condom, partner with
             surgical sterilization, etc.

         24. Use of other investigational products within the past 1 month

         25. Subject who are judged by the investigator unsuitable to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chong-Jin Kim</last_name>
    <role>Study Director</role>
    <affiliation>KyungHee University Hospital at Gangdong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Catholic University of Korea Bucheon St. Mary's Hospital</name>
      <address>
        <city>Wonmi-gu</city>
        <state>Bucheon</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busanjin-gu</city>
        <state>Busan</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Seo-gu</city>
        <state>Busan</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Joong-gu</city>
        <state>Daegu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Joong-gu</city>
        <state>Daegu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Nam- gu</city>
        <state>Daegu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dongguk University Ilsan Hospital</name>
      <address>
        <city>Ilsandong-gu</city>
        <state>Goyang-si, Gyeoggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Dong-Gu</city>
        <state>Gwangju</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic University of Korea Uijeongbu St. Mary's hospital</name>
      <address>
        <city>Uijeongbu-si</city>
        <state>Gyeoggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Hospital</name>
      <address>
        <city>Namdong-gu</city>
        <state>Incheon</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Carollo General Hospital</name>
      <address>
        <city>Suncheon-si</city>
        <state>Jeollanam-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wonju Severance Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <state>Kangwon-Do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic University of Korea St. Paul's Hospital</name>
      <address>
        <city>Dongdaemun-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KyungHee University Medical Center</name>
      <address>
        <city>Dongdaemun-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Kangdong Sacred Heart Hospital</name>
      <address>
        <city>Gangdong-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital at Gangdong</name>
      <address>
        <city>Gangdong-Gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VHS( Veterans Medical Service) Medical Center</name>
      <address>
        <city>Gangdong-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Gwangjin-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Jongro-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic University of Korea Seoul St. Mary's Hospital</name>
      <address>
        <city>Seocho-Gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seongbuk-Gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic University of Korea Yeouido St. Mary's Hospital</name>
      <address>
        <city>Yeongdeungpo-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Dong-gu</city>
        <state>Ulsan</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2016</study_first_submitted>
  <study_first_submitted_qc>October 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2016</study_first_posted>
  <last_update_submitted>November 21, 2016</last_update_submitted>
  <last_update_submitted_qc>November 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Candesartan</keyword>
  <keyword>Amlodipine</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Antihypertensive Agents</keyword>
  <keyword>Vasodilator Agents</keyword>
  <keyword>Angiotensin II Type 1 Receptor Blockers</keyword>
  <keyword>Angiotensin Receptor Antagonists</keyword>
  <keyword>Calcium Channel Blockers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Angiotensin II Type 1 Receptor Blockers</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

